References

The Parkinson's-Reversing Breakthrough

What is Parkinsons Disease

Get Instant Access

1. Petroff OA, Mattson RH, Rothman DL. Proton MRS: GABA and glutamate. Adv Neurol 2000; 83:261-271.

2. Fazekas F, Barkhof F, Filippi M, et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 1999; 53:448-456.

3. Baird A, Warach S. Imaging developing brain infarction. Curr Opin Neurol 1999; 12:65-71.

4. Phelps M. Positron emission tomography (PET). In: Mazziota J, Gilman S, eds. Clinical Brain Imaging: Principles and Applications. F.A. Davis: Philadelphia, 1992:71-107.

5. Lassen N, Holm S. Single photon emission computerized tomography (SPECT). In: Mazziota J, Gilman S, eds. Clinical Brain Imaging: Principles and Applications. F.A. Davis: Philadelphia, 1992:108-134.

6. Eidelberg D, Edwards C. Functional brain imaging of movement disorders. Neurol Res 2000; 22:305-312.

7. Leenders K, Antonini A. PET 18F-Fluordopa (FD) uptake and disease progression in Parkinson's disease. Neurology 1995; 45:A220.

8. Brooks DJ. Advances in imaging Parkinson's disease. Curr Opin Neurol 1997; 10:327-331.

9. Eidelberg D, Moeller J, Ishikawa M, et al. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995; 45:1995- 2004.

10. Piccini P, Brooks DJ. Etiology of Parkinson's disease: contributions from 18F-DOPA positron emission tomography. Adv Neurol 1999; 80:227-231.

11. Sawle G, Playford E, Burn D, Cunnigham V, Brooks D. Separating Parkinson's disease from normality: discriminant function analysis of [18F] dopa PET data. Arch Neurol 1994; 51:237-243.

12. Snow B, Tooyama I, McGeer E, Calne D. Human positron emission tomographic [18F]flouordopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993; 34:324-330.

13. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996; 40:873-884.

14. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000; 47:493-503.

15. Frey K, Koeppe R, Kilbourn M. Imaging the vesicular monoamine transporter. Adv Neu-rol 2001; 86:237-247.

16. Asenbaum S, Brucke T, Pirker W, et al. Imaging of dopamine transporters with iodine-123-B-CIT and SPECT in Parkinson's disease. J Nucl Med 1997; 38:1-6.

17. Booij J, Tissingh G, Boer GJ, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62:133-140.

18. Fischman AJ, Bonab AA, Babich JW, et al. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse 1998; 29:128-141.

19. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 1993; 90:11965-11969.

20. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38:589-598.

21. Tatsch K, Schwarz J, Mosley P, et al. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med 1997; 24:415-421.

22. Huang WS, Lin SZ, Lin JC, Wey SP, Ting G, Liu RS. Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging. J Nucl Med 2001; 42:1303-1308.

23. Lehericy S, Brandel JP, Hirsch EC, et al. Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrote-trabenazine autoradiography. Brain Res 1994; 659:1-9.

24. Kaufman M, Madras B. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 1991; 9:43-49.

25. Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in Parkin-sonian putamen and reduced in the caudate nucleus. J Neurochem 1991; 56:192-198.

26. Marek K. Dopaminergic dysfunction in parkinsonism: new lessons from imaging. Neu-roscientist 1999; 5:333-339.

27. Frey KA, Koeppe RA, Kilbourn MR. Imaging the vesicular monoamine transporter. Adv Neurol 2001; 86:237-247.

28. Brooks DJ. Positron emission tomography studies in movement disorders. Neurosurg Clin N Am 1998; 9:263-282.

29. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatric Psychiatry 2002; 10:36-43.

30. Pate BD, Kawamata T, Yamada T, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993; 34:331-338.

31. Liu Y, Edwards RH. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Ann Rev Neurosci 1997; 20:125-156.

32. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995; 294:577-583.

33. Kilbourn MR, Kuszpit K, Sherman P. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse 2000; 35:250-255.

34. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001; 21:6853-6861.

35. Elsworth JD, al-Tikriti MS, Sladek JR, et al. Novel radioligands for the dopamine transporter demonstrate the presence of intrastriatal nigral grafts in the MPTP-treated monkey: correlation with improved behavioral function. Exp Neurol 1994; 126:300-304.

36. Boja J, Patel A, Carroll F, et al. [125I]-RTI-55: a potent ligand for dopamine transporters. Eur J Pharmacol 1991; 194:133-134.

37. Brouard A, Pelaprat D, Boja JW, et al. Potent cocaine analogs inhibit [3H]dopamine uptake in rat mesencephalic cells in primary cultures: pharmacological selectivity of embryonic cocaine sites. Brain Res Dev Brain Res 1993; 75:13-17.

38. Coulter CL, Happe HK, Bergman DA, Murrin LC. Localization and quantification of the dopamine transporter: comparison of [3H]WIN 35,428 and [125I]RTI-55. Brain Res 1995; 690:217-224.

39. Fujita M, Shimada S, Fukuchi K, Tohyama M, Nishimura T. Distribution of cocaine recognition sites in rat brain: in vitro and ex vivo autoradiography with [125I]RTI-55. J Chem Neuroanat 1994; 7:13-23.

Staley JK, Basile M, Flynn DD, Mash DC. Visualizing dopamine and serotonin transporters in the human brain with the potent cocaine analogue [125I]RTI-55: in vitro binding and autoradiographic characterization. J Neurochem 1994; 62:549-556. Volkow ND, Gatley SJ, Fowler JS, et al. Long-lasting inhibition of in vivo cocaine binding to dopamine transporters by 3 beta-(4-iodophenyl)tropane-2-carboxylic acid methyl ester: RTI-55 or beta CIT. Synapse 1995; 19:206-211.

Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med 1996; 37:1129-1133.

Laruelle M, Wallace E, Seibyl JP, et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994; 14:982-994.

Seibyl J, Marek K, Sheff K, Innis R. Within-subject comparison of [123I]FP-CIT and [123I]B-CIT for SPECT imaging of dopamine transporters in Parkinson's disease. Neurology 1996; 46:A456.

Kung MP, Stevenson DA, Plossl K, et al. [99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med 1997; 24:372-380. Frost JJ, Rosier AJ, Reich SG, et al. Positron emission tomography imaging of the dopamine transporter with 11C WIN 35,428 reveals marked decline in mild Parkinson's disease. Ann Neurol 1993; 34:423-431.

Rinne JO, Laihinen A, Nagren K, Ruottinen H, Ruotsalainen U, Rinne UK. PET examination of the monoamine transporter with [11C]beta-CIT and [11C]beta-CFT in early Parkinson's disease. Synapse 1995; 21:97-103.

Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 2002; 73: 529-534. Rosati G, Granieri E, Pinna L, et al. The risk of Parkinson disease in Mediterranean people. Neurology 1980; 30:250-255.

Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 1995; 142:820-827.

Martilla R, Rinne U. Epidemiology of Parkinson's disease in Finland. Acta Neurol Scan 1967; 43(suppl 33):9-61.

Rajput A, Rodzilsky B, Rajput A. Accuracy of clinical diagnosis of Parkinsonism—a prospective study. Can J Neurol Sci 1991; 18:275-278.

Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:1142-1146.

Quinn N. Parkinsonism—recognition and differential diagnosis. BMJ 1995; 310:447-452. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999; 28:99-102.

Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42: 1142-1146.

Richards M, Stern Y, Mayeux R. Subtle extrapyramidal signs can predict the development of dementia in elderly individuals. Neurology 1993; 43:2184-2188. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996; 334:71-76. Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Arch Neurol 2000; 57:369-372.

Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125:861-870. Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 1993; 115:1-17.

Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. New Eng J Med 1988; 318:876-880. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988; 24:574-576.

64. Fearnley J, Lees A. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114:2283-2301.

65. Morrish P, Sawle G, Brooks D. Clinical and [18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995; 59:597-600.

66. Marek K, Seibyl J, Scanley B, et al. [I 123]CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi Parkinson's disease. Neurology 1996; 46:231-237.

67. Guttman M, Burkholder J, Kish S, et al. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease. Neurology 1997; 48:1578-1583.

68. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa. The REAL-PET study. Ann Neurol 2003; 54:93-101.

69. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351:2498-2508.

70. Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporter with [123I]FP-CIT SPET in differentiating patients with presynap-tic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28:266-272.

71. Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K. [123I]B-CIT and SPECT imaging versus clinical evalaution in parkinsonian syndrome: Unmasking an early diagnosis. Arch Neurol 2004; 61:1224-1229.

72. Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998; 105:1213-1228.

73. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP CIT study group. Mov Disord 2000; 15:503-510.

74. Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with Dopascan™/SPECT in parkinsonism. Neurology 2000; 55:1540-1547.

75. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000; 15:692-698.

76. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997; 41:58-64.

77. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-442.

78. Gerschlager W, Bencsits G, Pirker W, et al. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 2002; 17:518-523.

79. Goldstein S, Friedman JH, Innis R, Seibyl J, Marek K. Hemi-parkinsonism due to a mid-brain arteriovenous malformation: dopamine transporter imaging. Mov Disord 2001; 16:350-353.

80. Brucke T, Asenbaum S, Pirker W, et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm 1997; 50:9-24.

81. Brooks D, Ibanez V, Sawle G, et al. Differing patterns of striatal 18F-DOPA uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990; 28:547-555.

82. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001; 16:1023-1032.

83. Eidelberg D, Dhawan V. Can imaging distinguish PSP from other neurodegenerative disorders? Neurology 2002; 58:997-998.

84. Antonini A, Kazumata K, Feigin A, et al. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Mov Disord 1998; 13:268-274.

85. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328:176-183.

86. Parkinson Study Group. Pramipexole vs levodopa as initial therapy for Parkinson's disease. JAMA 2000; 284:1931-1938.

Rascol O, Brooks D, Korczyn A, De Deyn P, Clarke C, Lang A. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342:1484-1491.

Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 2000; 15:485-489.

Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol 1999; 56:529-535.

Marek K, Innis R, van Dyck C, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001; 57:2089-2094. Morrish P, Rakshi J, Bailey D, Sawle G, Brooks D. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F}dopa PET. J Neurol Neurosurg Psychiatry 1998; 64:314-319.

Nurmi E, Ruottinen H, Kaasinen V, et al. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol 2000; 47:804-808.

Nurmi E, Ruottinen H, Bergman J, et al. Rate of progression in Parkinson's disease: A 6-[18F]fluoro-L-dopa PET study. Mov Disord 2001; 16:608-615.

Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal ß-CIT SPECT study. Mov Disord 2002; 17:45-53.

Sawle GV , Myers R. The role of positron emission tomography in the assessment of human transplantation. Trends Neurosci 1993; 16:260-264.

Nakamura T, Dhawan V, Chaly T, et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol 2001; 50:181-187. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996; 19:102-109.

Maroney AC, Finn JP, Bozyczko-Coyne D, et al. CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults. J Neurochem 1999; 73:1901-1912. Tatton WG, Chalmers-Redman RM, Ju WJ, et al. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 2002; 301:753-764. Shults CW, Schapira AH. A cue to queue for CoQ? Neurology 2001; 57:375-376. Brooks DJ. Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET. J Neural Transm Suppl 2000; 60:125-137.

Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287:1653-1661. Nutt J, Holford N. The response of levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996; 39:561-573.

Ceravolo R., Piccini P, Bailey DL, Jorga KM, Bryson H, Brooks DJ. 18f-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 2002; 43:201-207.

Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 1990; 13:290-296.

Nurmi E, Bergman J, Eskola O, et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cereb Blood Flow Metab 2000; 20:1604-1609.

Innis R, Marek K, Sheff K, et al. Treatment with carbidopa/levodopa and selegiline on striatal transporter imaging with [123I]B-CIT. Mov Disord 1999; 14:436-443. Ahlskog JE, Uitti RJ, O'Connor MK, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999; 14:940-946. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001; 56:1559-1564. Marek K, Jennings DL, Tabamo R, Seibyl JP. INSPECT: An investigation of the effects of short-term treatment with pramipexole or levodopa on [123I]b-CIT and SPECT imaging in early Parkinson disease. Neurology 2006; 66(suppl 2):A112.

111. Golbe LI. The genetics of Parkinson's disease: A reconsideration. Neurology 1990; 40(suppl 3):7-16.

112. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996; 119( Pt 2):585-591.

113. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56:173-181.

114. Piccini P, Morrish PK, Turjanski N, et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol 1997; 41:222-229.

115. Burn DJ, Mark MH, Playford ED, et al. Parkinson's disease in twins studied with 18F dopa and positron emission tomography. Neurology 1992; 42:1894-1900.

116. Snow BJ, Peppard RF, Guttman M, Calne DB. Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. Arch Neurol 1990; 47:870-874.

117. Nicholl DJ, Vaughan JR, Khan NL, et al. Two large British kindreds with familial Parkinson's disease: a clinico-pathological and genetic study. Brain 2002; 125:44-57.

118. Kruger R, Kuhn W, Leenders KL, et al. Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 2001; 56:1355-1362.

119. Brooks D, Ibanez V, Sawle G, et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31:184-192.

120. Antonini A, Schwarz J, Oertel W, Beer H, Madejo U, Leenders K. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994; 44:1325-1329.

121. Tatsch K, Schwarz J, Oertel W, Kirsch C. Dopamine D2 receptor imaging with I-123 IBZM SPECT to differentiate idiopathic from other parkinson syndromes. J Nucl Med 1992; 33:917-918.

122. Piccini P, Brooks DJ, Bjorklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999; 2:1137-1140.

Was this article helpful?

0 0
Defeat Drugs Death

Defeat Drugs Death

This Book Is One Of The Most Valuable Resources In The World When It Comes To Helpful Info On Avoiding And Beating A Fatal Drug Addiction!

Get My Free Ebook


Post a comment